Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 19/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | FES | P07332 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | ROS1 | P08922 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682878 | 0.90 | PTK2 (0.65) | PTK2LCKFYNFESRET | |
| SCHEMBL1682871 | 0.88 | PTK2 (0.62) | PTK2LCKFYNFESRET | |
| SCHEMBL1682837 | 0.87 | PTK2 (0.60) | PTK2LCKFYNFESRET | |
| SCHEMBL1682811 | 0.86 | PTK2 (0.71) | PTK2LCKFYNFESRET | |
| SCHEMBL1682819 | 0.85 | PTK2 (0.57) | PTK2LCKFYNFESRET | |
| SCHEMBL13557788 | 0.85 | PTK2 (0.58) | PTK2LCKFYNFESRET | |
| SCHEMBL1682793 | 0.85 | PTK2 (0.83) | PTK2LCKFYNFESRET | |
| SCHEMBL1682881 | 0.83 | PTK2 (0.57) | PTK2LCKFYNFESRET | |
| SCHEMBL12801731 | 0.82 | PTK2 (0.72) | PTK2LCKFYNFESRET | |
| SCHEMBL1682851 | 0.82 | PTK2 (0.61) | PTK2LCKFYNFESRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586580-B2 | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | claimed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | claimed |
| US-8586580-B2 | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| EP-2491043-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KIST Korea Institute of Science and Technology (KR) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049332-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK2, TK1, DTYMK | PTK2 292/4885LCK 327/4885FYN 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.